ICICI Prudential Nifty Pharma Index Fund Regular Growth
NAV ₹21.5454 on 13 November 2026
AMFI name: ICICI Prudential Nifty Pharma Index Fund - Growth · Scheme code 150929 · ISIN INF109KC18L6
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY PHARMA TRI |
|---|---|---|
| 1M | +10.80% | +9.46% |
| 6M | +15.63% | +19.86% |
| 1Y | +25.10% | +26.54% |
| 3Y | +21.90% | +23.39% |
| 5Y | - | +16.53% |
Benchmark: NIFTY PHARMA TRI (total return index), measured over the same dates.
Risk
From daily NAVs. Alpha, beta and capture are measured against NIFTY PHARMA TRI.
- Volatility
- 15.29%
- Annualised, 3 years
- Max drawdown
- -16.78%
- Worst fall from a peak, 3 years
- Sharpe ratio
- 1.04
- Return above the risk-free rate per unit of volatility, 3 years
- Sortino ratio
- 1.51
- Like Sharpe, counting only falls, 3 years
- Alpha
- -1.23%
- Return a year beyond what beta explains, 3 years
- Beta
- 1.00
- 1.00 moves in step with the benchmark, 3 years
- Upside capture
- 98%
- Share of the benchmark's rises captured, 3 years
- Downside capture
- 100%
- Share of the benchmark's falls taken (lower is better), 3 years
Every 3-year holding period
Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.
Costs and fund facts
- Exit load
- Nil
- Fund size (all plans)
- ₹151 CrAverage, quarter to September 2026
- Benchmark
- NIFTY PHARMA TRI
- Allotment date
- 14 December 2022Scheme document
- Type
- Open Ended
- AMFI scheme code
- 150929
Fund managers (3)
- Nishit Patel
- Ashwini Bharucha
- Venus Ahuja
How each manager has done since taking over: fund manager scorecard.
Investment objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
About this fund
ICICI Prudential Nifty Pharma Index Fund Regular Growth is a mutual fund scheme from ICICI Prudential Mutual Fund, listed by AMFI under “Other Scheme - Index Funds”. This page covers the Regular plan with the Growth option. Its NAV was ₹21.5454 on 13 November 2026. It returned 25.10% over 1 year and 21.90% a year over 3 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY PHARMA TRI, returned 23.39% a year over 3 years. For an index fund or ETF, how closely it tracks its index matters more than its rank against other passive funds. Its average assets under management were ₹151 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Managed by Nishit Patel, Ashwini Bharucha and Venus Ahuja. Its scheme summary document gives the allotment date as 14 December 2022.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns. Compare tracking difference across index funds.